{{Drugbox
| IUPAC_name = (3S)-3-<nowiki/>{[(2S)-2-<nowiki/>{[2-(2-tert-butylanilino)-2-oxoacetyl]amino}propanoyl]amino}-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
| image = Emricasan_structure.png
<!--Clinical data-->
| tradename = Emricasan
| legal_US = Investigational New Drug
| legal_status = 
<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 254750-02-2
| PubChem = 12000240
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = P0GMS9N47Q
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChemSpiderID = 10172707
| KEGG = D10004
<!--Chemical data-->
| C=26 | H=27 | F=4 | N=3 | O=7
| molecular_weight = 569.501
| SMILES = C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COc1c(c(cc(c1F)F)F)F)NC(=O)C(=O)Nc2ccccc2C(C)(C)C
| StdInChI = 1S/C26H27F4N3O7/c1-12(31-24(38)25(39)32-16-8-6-5-7-13(16)26(2,3)4)23(37)33-17(10-19(35)36)18(34)11-40-22-20(29)14(27)9-15(28)21(22)30/h5-9,12,17H,10-11H2,1-4H3,(H,31,38)(H,32,39)(H,33,37)(H,35,36)/t12-,17-/m0/s1
| StdInChIKey = SCVHJVCATBPIHN-SJCJKPOMSA-N
}}

'''Emricasan''' ('''IDN-6556''', '''PF-03491390''') is a drug originally invented by [[Pfizer]] and licensed for development to Conatus Pharmaceuticals, which acts as a [[caspase]] inhibitor and has [[antiinflammatory]] effects. It was developed for the treatment of liver disease,<ref>Hoglen NC, Chen LS, Fisher CD, Hirakawa BP, Groessl T, Contreras PC. Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor. ''J Pharmacol Exp Ther''. 2004 May;309(2):634-40. {{PMID|14742742}}</ref> and has been granted fast track designation by the FDA for development after positive results in Phase II clinical trials for [[non-alcoholic fatty liver disease]].<ref>Haddad JJ. Current opinion on 3-[2-[(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]- 4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid, an investigational drug targeting caspases and caspase-like proteases: the clinical trials in sight and recent anti-inflammatory advances. ''Recent Pat Inflamm Allergy Drug Discov''. 2013 Sep;7(3):229-58. {{PMID|23859695}}</ref><ref>Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. ''Gut''. 2016 Sep 19. pii: gutjnl-2016-312431. doi: 10.1136/gutjnl-2016-312431. {{PMID|27646933}}</ref> Emricasan is the first caspase inhibitor developed for clinical use, and this novel mechanism of action has led to interest in research using emricasan for other potential applications such as an anti-cancer or antiviral drug.<ref>Brumatti G, Ma C, Lalaoui N, Nguyen NY, Navarro M, Tanzer MC, Richmond J, Ghisi M, Salmon JM, Silke N, Pomilio G, Glaser SP, de Valle E, Gugasyan R, Gurthridge MA, Condon SM, Johnstone RW, Lock R, Salvesen G, Wei A, Vaux DL, Ekert PG, Silke J. The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia. ''Sci Transl Med''. 2016 May 18;8(339):339ra69. doi: 10.1126/scitranslmed.aad3099. {{PMID|27194727}}</ref><ref>Xu M, Lee EM, Wen Z, Cheng Y, Huang WK, Qian X, Tcw J, Kouznetsova J, Ogden SC, Hammack C, Jacob F, Nguyen HN, Itkin M, Hanna C, Shinn P, Allen C, Michael SG, Simeonov A, Huang W, Christian KM, Goate A, Brennand KJ, Huang R, Xia M, Ming GL, Zheng W, Song H, Tang H. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. ''Nat Med''. 2016 Oct;22(10):1101-1107. doi: 10.1038/nm.4184. {{PMID|27571349}}</ref>

==References==
{{Reflist}}

[[Category:Enzyme inhibitors]]
[[Category:Tert-butyl compounds]]
[[Category:Fluoroarenes]]

{{pharm-stub}}